Phase 2 N=93 Androgen Effect on Klinefelter Syndrome Motor Outcome
Klinefelter Syndrome
Primary: Motor Function/Strength — 86; 81; 92; 89 score on a scale — p=0.005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=200 A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
Squamous Non-small Cell Lung Cancer
Primary: Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment — 7.3; 4.2 months
N/A N=805 Product Performance of a New Silicone Hydrogel Contact Lens
Myopia
Primary: Mean Change in logMAR Contact Lens Visual Acuity — -0.056; -0.069; -0.069 logMAR
Phase 2 N=14 BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
B-cell Lymphoma · Chronic Lymphocytic Leukaemia · Waldenström Macroglobulinemia
Primary: Documenting Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters…
N/A N=300 Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II
Overweight and Obesity · Health Behavior · Sleep Deprivation
Primary: Healthy Eating Index (HEI) — 52.6; 53.8 units on a scale
Phase 3 N=402 Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Multiple Myeloma
Primary: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) — 13.93; 9.46 Months — p=0.0075
Phase 2 N=25 The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates
Diabetic Macular Edema · Hard Lipid Exudates
Primary: Best Corrected Visual Acuity as Measured by ETDRS at 6 and 12 Months — 78; 73.92; 77.92; 74.83 letters read correctly
Phase 2 N=46 Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Brain Tumors
Primary: Event-free Survival (EFS)
Phase 4 N=67 Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines
Hepatitis B · Hepatitis · Hepatitis, Viral, Human
Primary: Number of Participants With Protective Levels of Antibodies After Treatment — 63; 4 Participants
N/A N=20 Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
Pediatric Cancer · Febrile Neutropenia · Chemotherapy-induced Neutropenia
Primary: Feasibility of Continous Monitoring of Heart Rate With the Wearable Device (WD) — 6 Participants
Phase 4 N=99 Pre-medication With Alfentanil vs Placebo During ECT
Blood Pressure · Electroconvulsive Therapy
Primary: Systolic Blood Pressure Change — 22.011; 38.908 mmHg
Phase 2 N=100 Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease
Dry Eye
Primary: Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1 — 7.9; 3.5 mm — p=0.1491
Phase 3 N=385 Combining Varenicline and Bupropion for Smoking Cessation
Smoking Cessation
Primary: Smoking Abstinence at 12 Months — 30; 33; 2 Participants
Phase 2 N=102 Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Part 1: Number of Participants With Potentially Clinically Significant Hematology Results by Treatment Group — 0; 0; 0; 0 Participants
Phase 1 N=6 Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Transitional Cell Carcinoma
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants